lifestyle.thenyctimes.com

Author: Femasys Inc.

Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

March 10, 2026
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

March 10, 2026
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 2, 2026
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

February 23, 2026
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products

February 10, 2026